---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-080613"
form_type: "8-K"
ticker: "LIMN"
cik: "0001971387"
company_name: "Liminatus Pharma, Inc."
filed_at: "2026-07-06T13:13:16+00:00"
generated_at: "2026-07-06T13:14:09.247772+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Liminatus Pharma closes merger with InnocsAI; issues 11.2M common shares and 158.9K Series A preferred

## Summary
- Merger closed July 2, 2026; Liminatus acquired InnocsAI, a CAR-T therapy company.
- Issued 11,188,729 common shares and 158,881.1271 Series A Preferred shares (each convertible into 10,000 common shares).
- Total consideration 1.6B shares at $0.20/share, but capped at 19.99% of pre-closing outstanding common stock.
- Series A Preferred non-voting, convertible only after stockholder approval; meeting to be held.
- Registration rights and non-compete agreements executed with InnocsAI members and key employees.

## SEC filing metadata
- accession: 0001104659-26-080613
- form_type: 8-K
- ticker: LIMN
- cik: 0001971387
- company_name: Liminatus Pharma, Inc.
- filed_at: 2026-07-06T13:13:16+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.01, 3.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971387/000110465926080613/0001104659-26-080613-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971387/000110465926080613/tm2619730d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-080613
- JSON: https://secwatch.observer/filing/0001104659-26-080613.json
- Plain text: https://secwatch.observer/filing/0001104659-26-080613.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.